Evercore ISI lowered the firm’s price target on Medtronic (MDT) to $108 from $115 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Medtronic price target lowered to $91 from $105 at Piper Sandler
- Edwards Lifesciences upgraded to Outperform from Peer Perform at Wolfe Research
- Medtronic price target raised to $120 from $118 at Barclays
- MiniMed initiated with a Buy at BofA